<DOC>
	<DOC>NCT01210495</DOC>
	<brief_summary>The study is designed to demonstrate that axitinib plus best supportive care is superior to placebo plus best supportive care in prolonging survival in patients with advanced hepatocellular carcinoma.</brief_summary>
	<brief_title>Axitinib For The Treatment Of Advanced Hepatocellular Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma, Hepatocellular</mesh_term>
	<mesh_term>Axitinib</mesh_term>
	<criteria>Locally advanced or metastatic HCC Failure of one prior antiangiogenic therapy including sorafenib, bevacizumab and brivanib. ChildPugh Class A or B (score 7 only) disease. Prior treatment of advanced HCC with more than one prior firstline systemic therapy. Any prior local therapy within 2 weeks of starting the study treatment. Presence of hepatic encephalopathy and/or clinically relevant ascites. Presence of main portal vein invasion by HCC.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Hepatocellular Carcinoma</keyword>
</DOC>